Stepan (SCL) Thin 2% Margin And EPS Slide Reinforce Bearish Narratives In FY 2025

Stepan (SCL) has wrapped up FY 2025 with fourth quarter revenue of US$553.9 million and basic EPS of US$0.22, while trailing twelve month figures show revenue of about US$2.3 billion and EPS of US$2.05. Over recent periods, revenue has moved from US$546.8 million in Q3 2024 to the US$590.3 million to US$594.7 million range across the first three quarters of 2025, with quarterly EPS ranging from US$0.47 to US$0.86, and trailing EPS shifting between US$2.01 and US$2.54. With a trailing net margin sitting at 2% and earnings under pressure in recent years, this latest set of numbers gives investors a fresh read on how well the business is holding its margin profile.

See our full analysis for Stepan.

With the headline figures on the table, the next step is to see how these results line up with the prevailing stories around Stepan and where the numbers push back on those narratives.

See what the community is saying about Stepan

Five year EPS slide of 28.5% keeps pressure on the story

• Over the past five years, Stepan's EPS has declined by 28.5% per year, while trailing twelve month EPS for FY 2025 sits at US$2.05 on about US$2.3b of revenue and a 2% net margin.
• Critics focus on this multi year earnings decline as a key risk, and the latest year of data does not contradict that concern.
  • Trailing net margin is 2%, slightly below the 2.3% margin recorded a year earlier, so profitability has not yet recovered in the trailing figures.
  • Net income on a trailing basis is US$46.9m, which is modest relative to the US$2.3b revenue base and keeps the bearish argument about thin profitability very much alive.

If you are wondering how cautious investors frame that earnings slide, bears set out their full argument in the 🐻 Stepan Bear Case.

2% margin and weaker cash coverage keep income investors wary

• The analysis flags a 2% trailing net margin and a 2.95% dividend yield that is not well covered by free cash flow, alongside a high level of debt on the balance sheet.
• Income focused bears highlight these figures as reasons to be careful, and the trailing numbers give them several talking points.
  • With US$46.9m of trailing net income supporting a dividend yield of 2.95%, there is limited room if cash generation does not match accounting profit.
  • The note on high leverage, combined with thin margins, means more of that earnings base may need to support debt rather than shareholder returns, which is exactly what the cautious narrative points to.

P/E of 25.8x and DCF fair value of US$145.89 contrast with US$53.53 share price

• On the trailing data, Stepan trades on a 25.8x P/E, below the US Chemicals industry at 28.6x and peers at 29.1x, while a DCF fair value of US$145.89 compares to a current share price of US$53.53.
• Supporters lean on this valuation gap as a bullish counterweight to weak earnings trends, and the inputs here are quite specific.
  • The P/E discount to both the industry and peer averages suggests the market is not paying the same multiple for Stepan's US$2.05 of trailing EPS as it is for comparable names.
  • The DCF fair value of US$145.89 sits well above the current US$53.53 share price in the dataset, which strongly supports the bullish view that the market may reassess the stock if fundamentals stabilize or improve.

If you want to see how bullish investors connect this valuation gap to Stepan's growth projects and margins, check out the full 🐂 Stepan Bull Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Stepan on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both cautious and optimistic takes on the table, do these numbers leave you comfortable or uneasy, and how quickly do you want to firm up your own stance given there are 1 key reward and 3 important warning signs worth weighing for yourself?

See What Else Is Out There

Thin 2% margins, a multi year EPS slide and pressure on dividend coverage and leverage all suggest Stepan is not a low risk income story right now.

If those pressure points feel a bit too tight for your comfort, take a few minutes to hunt through 80 resilient stocks with low risk scores that focus on steadier earnings and balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com